Transcription profiling of PfSPZ Malaria Vaccine trial subjects receiving a 3-dose regimen in a malaria endemic region

The Sanaria® PfSPZ Vaccine can confer sterilizing protection against liver stage infection by Plasmodium falciparum (Pf) in malaria naïve individuals. The vaccine consists of aseptically purified irradiated Pf sporozoites. Vaccinees received 3 doses of 1.8 X 106 irradiated sporozoites. Efficacy was measured by challenged by controlled human malaria infections (CHMI), and against naturally occurring Pf Infections in Malian adults during the malaria transmission season 32 samples from 2 time points, pre-vaccination (Day -7) and post-vaccination (Day 116), for 16 Malian adult participants who all received 3 doses of the PfSPZ vaccine. All subjects remained uninfected after CHMI and 9 participants remained uninfected during the subsequent malaria season